Please assess the completion status of the following clinical trial:

Trial Title: Omega-3 and Therapy Study for Childhood Bipolar Disorder- Not Otherwise Specified

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 7-14 years (boys and girls)~* Has a diagnosis of BP-NOS according to the LAMS definition. Criteria as follows:~* Clinically significant bipolar symptoms that do not meet DSM IV TR criteria for bipolar disorder I or bipolar disorder II~* Elated mood plus 2 or more associated symptoms from DSM IV TR or irritable mood plus 3 or more symptoms~* A change in functioning, and a minimum duration of 4 hours within a 24-hour period and at least 4 cumulative lifetime days meeting criteria~* Full scale IQ ≥ 70~* Child and one parent or other caregiver must be able to complete all assessment~* Child must be able to swallow capsules (training in swallowing will be offered)~* Parent and child must be willing to have blood drawn from child at two study assessments.~Exclusion Criteria:~* Major medical disorders (eg diabetes, epilepsy, metabolic disorder)~* Inability to communicate in English~* Lack of access via phone~* Autism~* Schizophrenia, or other psychotic states warranting anti-psychotic medication~* Active suicidal concern (e.g., I want to kill myself, a plan for suicide, or an attempt in the past month; however, passive suicidal ideation, such as I wish I were dead would not exclude)~* Three or more symptoms rated as marked or severe on the KDRS or KMRS~* Concurrent mental health intervention (pharmacotherapy and/or psychotherapy) in the past month.

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Supplement and No PEP (Type: PLACEBO_COMPARATOR): Will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.
- Omega-3 and PEP (Type: EXPERIMENTAL): Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment.
- Omega-3 and No PEP (Type: EXPERIMENTAL): Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.
- Placebo Supplement and PEP (Type: EXPERIMENTAL): Placebo Supplement will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).